Nothing Special   »   [go: up one dir, main page]

CR20190417A - Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas - Google Patents

Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas

Info

Publication number
CR20190417A
CR20190417A CR20190417A CR20190417A CR20190417A CR 20190417 A CR20190417 A CR 20190417A CR 20190417 A CR20190417 A CR 20190417A CR 20190417 A CR20190417 A CR 20190417A CR 20190417 A CR20190417 A CR 20190417A
Authority
CR
Costa Rica
Prior art keywords
par2
antibodies
antigen
binding fragments
binding
Prior art date
Application number
CR20190417A
Other languages
English (en)
Inventor
Claire Dobson
David Fairman
Peter Thornton
Richard Williams
Philip Newton
Ian Gurrell
Sadhana Podichetty
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CR20190417A publication Critical patent/CR20190417A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno capaces de unirse a PAR2. En algunas realizaciones, los anticuerpos anti-PAR2 o fragmentos de unión a antígeno de los mismos se unen a PAR2 de una manera dependiente del pH. La divulgación proporciona además métodos para preparar y usar los anticuerpos y fragmentos de unión a antígeno.The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
CR20190417A 2017-03-16 2018-03-16 Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas CR20190417A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US201862637766P 2018-03-02 2018-03-02
PCT/EP2018/056776 WO2018167322A1 (en) 2017-03-16 2018-03-16 Anti-par2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20190417A true CR20190417A (es) 2019-12-06

Family

ID=61827709

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190417A CR20190417A (es) 2017-03-16 2018-03-16 Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas

Country Status (20)

Country Link
US (3) US10836822B2 (es)
EP (1) EP3596125A1 (es)
JP (2) JP7222901B2 (es)
KR (1) KR102711884B1 (es)
CN (1) CN110446720B (es)
AU (2) AU2018235031B2 (es)
BR (1) BR112019018752A2 (es)
CA (1) CA3055251A1 (es)
CL (1) CL2019002626A1 (es)
CO (1) CO2019010975A2 (es)
CR (1) CR20190417A (es)
IL (1) IL269134B2 (es)
MA (1) MA49886A (es)
MX (1) MX2019010802A (es)
NZ (1) NZ757915A (es)
PH (1) PH12019502087A1 (es)
SG (1) SG11201908056QA (es)
TW (1) TWI788332B (es)
UA (1) UA125757C2 (es)
WO (1) WO2018167322A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2275443E (pt) 2008-04-11 2016-03-15 Chugai Pharmaceutical Co Ltd Moléculas de ligação ao antigénio capazes de se ligarem, repetidamente, a duas ou mais moléculas de antigénio
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20180054923A (ko) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
PL3233921T3 (pl) 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
CN114773469A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
JP2023538379A (ja) * 2020-08-18 2023-09-07 セファロン エルエルシー 抗par-2抗体及びそれらの使用方法
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024156720A1 (en) 2023-01-25 2024-08-02 Medimmune Limited Migraine therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1604207A2 (en) * 2003-03-11 2005-12-14 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
WO2006052723A2 (en) * 2004-11-04 2006-05-18 New England Medical Center Hospitals, Inc. G protein coupled receptor agonists and antagonists and methods of use
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
PT2275443E (pt) 2008-04-11 2016-03-15 Chugai Pharmaceutical Co Ltd Moléculas de ligação ao antigénio capazes de se ligarem, repetidamente, a duas ou mais moléculas de antigénio
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
JP2011530515A (ja) 2008-08-05 2011-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Par−2活性化のエフェクターおよび炎症の調節におけるその使用
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
PE20130393A1 (es) 2010-03-11 2013-04-07 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente de ph
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
KR20150041662A (ko) * 2012-08-13 2015-04-16 리제너론 파아마슈티컬스, 인크. Ph-의존적 결합 특성을 갖는 항-pcsk9 항체
JP7037885B2 (ja) * 2014-06-30 2022-03-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング pH依存性抗原結合を示す抗TNFa抗体

Also Published As

Publication number Publication date
IL269134B2 (en) 2024-07-01
US20230242639A1 (en) 2023-08-03
AU2018235031B2 (en) 2021-08-12
US20210061905A1 (en) 2021-03-04
IL269134A (en) 2019-11-28
AU2018235031A1 (en) 2019-10-31
US11591389B2 (en) 2023-02-28
TW201843176A (zh) 2018-12-16
MA49886A (fr) 2020-06-24
CA3055251A1 (en) 2018-09-20
EP3596125A1 (en) 2020-01-22
KR102711884B1 (ko) 2024-10-02
NZ757915A (en) 2023-05-26
JP2023055895A (ja) 2023-04-18
UA125757C2 (uk) 2022-06-01
CO2019010975A2 (es) 2019-10-21
US20180305450A1 (en) 2018-10-25
JP7222901B2 (ja) 2023-02-15
JP2020509762A (ja) 2020-04-02
BR112019018752A2 (pt) 2020-05-05
IL269134B1 (en) 2024-03-01
CN110446720B (zh) 2023-09-12
CL2019002626A1 (es) 2019-12-06
AU2021257983A1 (en) 2021-11-25
KR20190129925A (ko) 2019-11-20
MX2019010802A (es) 2019-10-30
WO2018167322A1 (en) 2018-09-20
PH12019502087A1 (en) 2020-03-09
US10836822B2 (en) 2020-11-17
TWI788332B (zh) 2023-01-01
SG11201908056QA (en) 2019-09-27
CN110446720A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
CO2019010975A2 (es) Anticuerpos anti-par2 y usos de los mismos
CL2018003378A1 (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno.
AR114002A1 (es) Anticuerpos a lilrb2
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
NI202000086A (es) Agentes vinculantes de psma y usos de los mismos
BR112018008867A2 (pt) anticorpos que se ligam especificamente a pd-1 e seus usos
CO2019014414A2 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
CO2019009365A2 (es) Anticuerpos anti-lag3
CU24481B1 (es) Moléculas de anticuerpo que se unen a lag-3
NI201800044A (es) Anticuerpos agonísticos que se unen específicamente a cd40 humano y métodos de uso
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
ECSP17029218A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
ECSP16068976A (es) Moléculas de anticuerpo que se unen a pd-1 y usos de las mismas
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
DOP2019000098A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
CL2020000920A1 (es) Anticuerpo monoclonal anti-il-5ra.
EA201990505A1 (ru) Анти-tigit антитела, анти-pvrig антитела и их комбинации
AR106572A1 (es) Inhibidores de asgr
EA202091181A2 (ru) Антитела и способы их применения